Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Association of Lifespan Cognitive Reserve Indicator With Dementia Risk in the Presence of Brain Pathologies
  2. Association of Silent Myocardial Infarction and Sudden Cardiac Death
  3. Processes of Care Associated With Risk of Mortality and Recurrent Stroke Among Patients With TIA and Nonsevere Ischemic Stroke
  4. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes
  5. P2Y12 Inhibitor Monotherapy Is Noninferior to Dual Antiplatelet Therapy After PCI
  6. Effect of 1-Month DAPT Followed by Clopidogrel vs 12-Month DAPT on Cardiovascular and Bleeding Events in Patients Receiving PCI
  7. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
  8. Cardiovascular Safety of Oral Semaglutide in Patients With Type 2 Diabetes
  9. 5α-Reductase Inhibitors Associated With Increased Time to Diagnosis and Mortality in Prostate Cancer
  10. Proton Pump Inhibitor All-Cause and Cause-Specific Mortality in US Veterans

Most Read This Week

Recently Updated